In this section

Chaidos Lab

Contact

Consultant haematologist and honorary senior lecturer at the Hammersmith Hospital and Imperial College London
Expertise in multiple myeloma, lymphoma, and stem cell transplantation

+44 (0)20 3313 4017
a.chaidos@imperial.ac.uk

Areas of research

Myeloma functional heterogeneity in clinical drug resistance and residual disease

Myeloma heterogeneity is the single most important obstacle for optimal therapeutic targeting. A complex genetic landscape, epigenetic mechanisms and cues from tumour microenvironments shape the phenotypic and functional diversification of myeloma cells, which underpins drug resistance and later relapsed disease. Differential transcriptional profiles and gene expression regulatory mechanisms at diagnosis and residual disease provide insight into the biology of drug resistance and reveal novel disease vulnerabilities.

The lab is particularly interested in the biology of BCL2 family proteins. BCL2 inhibition is a promising targeted therapy for t(11;14) myeloma and a unique paradigm of treatment directed by genetics.

Myeloma kidney disease and MGRS

Myeloma kidney disease is a debilitating complication with a profound impact on treatment outcome and survival. Monoclonal Gammopathy of Renal Significance (MGRS) is a rare disease, where small amounts of highly nephrotoxic immunoglobulins or free light chains, produced by otherwise subclinical plasma cell clones, resulting in a bewildering array of renal histopathology and kidney disease.

The lab collaborates with Renal Medicine and Histopathology at Imperial to establish experimental vitro and vivo models of myeloma cast nephropathy and MGRS. We study the proinflammatory and profibrotic pathways induced by the nephrotoxic immunoglobulins and develop novel diagnostics and therapeutic strategies.

Citation

BibTex format

@inproceedings{Monsalvo:2016,
author = {Monsalvo, S and Sevillano, B and Innes, AJ and Lasa, M and Skinner, L and Stumpfle, R and Altaf, S and Yebra, E and Macdonald, D and Milojkovic, D and Chaidos, A and Gabriel, I and Brett, S and Broomhead, R and Patel, P and Waheed, U and Pavlu, J and Palanicawandar, R and Kanfer, E and Szydlo, R and Apperley, J and Olavarria, E},
pages = {5987--5987},
publisher = {American Society of Hematology},
title = {The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions},
year = {2016}
}

Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AU  - Monsalvo,S
AU  - Sevillano,B
AU  - Innes,AJ
AU  - Lasa,M
AU  - Skinner,L
AU  - Stumpfle,R
AU  - Altaf,S
AU  - Yebra,E
AU  - Macdonald,D
AU  - Milojkovic,D
AU  - Chaidos,A
AU  - Gabriel,I
AU  - Brett,S
AU  - Broomhead,R
AU  - Patel,P
AU  - Waheed,U
AU  - Pavlu,J
AU  - Palanicawandar,R
AU  - Kanfer,E
AU  - Szydlo,R
AU  - Apperley,J
AU  - Olavarria,E
EP  - 5987
PB  - American Society of Hematology
PY  - 2016///
SN  - 0006-4971
SP  - 5987
TI  - The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions
ER  -

Download